Showing results (141-150 of 257) with videos related to
Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CMLFrancesca Palandri, Ilaria Iacobucci, Giovanni Martinelli, et al.Annals of Hematology|October 12, 2012
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemiaMario Tiribelli, Roberto Latagliata, Luigiana Luciano, et al.Frontiers in Oncology|September 12, 2025
The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trialFabio Efficace, Laura Cannella, Isabella Capodanno, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid LeukemiaSimona Soverini, Giovanni Martinelli, Gianantonio Rosti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNetMichele Baccarani, Jorge Cortes, Fabrizio Pane, et al.Blood|August 8, 2008
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trialsSusan Branford, Linda Fletcher, Nicholas C P Cross, et al.Haematologica|June 11, 2010
The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working PartyIlaria Iacobucci, Annalisa Lonetti, Francesca Paoloni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysisFausto Castagnetti, Nicoletta Testoni, Simona Luatti, et al.Haematologica|January 16, 2009
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-upFrancesca Palandri, Fausto Castagnetti, Giuliana Alimena, et al.Blood|October 25, 2013
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHDAttilio Olivieri, Michele Cimminiello, Paolo Corradini, et al.Pageof 26